Business Wire06.05.17
NAMSA, the world’s only medical research organization (MRO) that accelerates medical device development through integrated laboratory, clinical and consulting services, is partnering with NAGLREITER Medical Device Development Organization (MDDO), a high-growth medical device design, development and manufacturing firm.
For nearly 50 years, NAMSA has offered services required to accelerate time-to-market and reduce costs for medical device research clients worldwide. Consistently recognized as a pioneer in medical device development, NAMSA has a proven and established track record of delivering expedited results through the utilization of its translational research methods.
NAGLREITER, similarly placing a significant concentration on providing efficacious customer outcomes, applies an integrated approach within its design, development and manufacturing service offerings. Providing end-to-end solutions for over 20 years, NAGLREITER focuses on technical and design alternatives that reduce costs and fast-track timelines that move clients into device production as quickly as possible.
“We are extremely excited about this unique partnership that will result in more predictable development timelines, increased cost savings and unparalleled time-to-market for device firms." said John Amat, NAMSA’s chief commercial officer. "NAGLREITER’s ‘Product Lifecycle Management’ methodology of innovation perfectly complements NAMSA’s ‘MRO Approach.’ Together, we will be able to more effectively drive start-up device programs and appropriately address the challenges and risks that these organizations face due to fragmented resources and increasingly complicated regulatory landscapes.”
This partnership, drawing upon a combined 70 years’ experience in assisting thousands of customers to successfully commercialize products throughout the world, will now provide early-stage medical device firms a single source, power house solution through its combined full service offering.
“NAGLREITER’s year-over-year success has opened up this exclusive opportunity to join forces with the leader in global medical device research," said Brett Naglreiter, president of NAGLREITER. "We fully expect our partnership to provide customers with further efficiencies that result from having access to a comprehensive portfolio of development resources and commercialization services that are managed through a single source.”
NAMSA accelerates medical device product development through integrated laboratory, clinical and consulting services. Driven by its regulatory expertise, NAMSA’s MRO approach plays an important role in translational research, applying a unique combination of disciplines—consulting, regulatory, preclinical, toxicology, microbiology, chemistry, clinical and quality—to move clients’ products through the development process, and continue to provide support through commercialization to post-market requirements.
NAGLREITER Medical Device Development Organization (MDDO) is a partner for concept incubation, design, development and manufacturing engineering services within the medtech industry. NAGLREITER prides itself on providing world-class services and employing a uniquely flexible business model to do so. NAGLREITER’s ‘The Right Path. With You’ business philosophy exemplifies the company’s commitment to partnering with clients to yield the best possible outcomes. Based in Miramar, Fla., NAGLREITER partners with medical device companies within the United States and abroad.
For nearly 50 years, NAMSA has offered services required to accelerate time-to-market and reduce costs for medical device research clients worldwide. Consistently recognized as a pioneer in medical device development, NAMSA has a proven and established track record of delivering expedited results through the utilization of its translational research methods.
NAGLREITER, similarly placing a significant concentration on providing efficacious customer outcomes, applies an integrated approach within its design, development and manufacturing service offerings. Providing end-to-end solutions for over 20 years, NAGLREITER focuses on technical and design alternatives that reduce costs and fast-track timelines that move clients into device production as quickly as possible.
“We are extremely excited about this unique partnership that will result in more predictable development timelines, increased cost savings and unparalleled time-to-market for device firms." said John Amat, NAMSA’s chief commercial officer. "NAGLREITER’s ‘Product Lifecycle Management’ methodology of innovation perfectly complements NAMSA’s ‘MRO Approach.’ Together, we will be able to more effectively drive start-up device programs and appropriately address the challenges and risks that these organizations face due to fragmented resources and increasingly complicated regulatory landscapes.”
This partnership, drawing upon a combined 70 years’ experience in assisting thousands of customers to successfully commercialize products throughout the world, will now provide early-stage medical device firms a single source, power house solution through its combined full service offering.
“NAGLREITER’s year-over-year success has opened up this exclusive opportunity to join forces with the leader in global medical device research," said Brett Naglreiter, president of NAGLREITER. "We fully expect our partnership to provide customers with further efficiencies that result from having access to a comprehensive portfolio of development resources and commercialization services that are managed through a single source.”
NAMSA accelerates medical device product development through integrated laboratory, clinical and consulting services. Driven by its regulatory expertise, NAMSA’s MRO approach plays an important role in translational research, applying a unique combination of disciplines—consulting, regulatory, preclinical, toxicology, microbiology, chemistry, clinical and quality—to move clients’ products through the development process, and continue to provide support through commercialization to post-market requirements.
NAGLREITER Medical Device Development Organization (MDDO) is a partner for concept incubation, design, development and manufacturing engineering services within the medtech industry. NAGLREITER prides itself on providing world-class services and employing a uniquely flexible business model to do so. NAGLREITER’s ‘The Right Path. With You’ business philosophy exemplifies the company’s commitment to partnering with clients to yield the best possible outcomes. Based in Miramar, Fla., NAGLREITER partners with medical device companies within the United States and abroad.